Tango Therapeutics, Inc.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing precision oncology by developing novel therapies for specific patient populations with significant unmet medical needs. The company's core strategy revolves around identifying and targeting genetic drivers of cancer to create highly effective and personalized treatments. Tango's pipeline is anchored by its innovative work on methylthioadenosine-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors. A key candidate in this class, TNG462, is currently undergoing Phase 1/2 clinical trials for pancreatic and lung cancers, aiming to address the limitations of existing treatment options. Furthermore, Tango is developing TNG456, a brain-penetrant PRMT5 inhibitor specifically designed to treat glioblastoma, a challenging form of brain cancer. The company is also exploring TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor, which holds promise in reversing immune evasion caused by serine-threonine kinase 11 loss-of-function mutations, particularly in lung cancer. By focusing on these distinct molecular targets and their associated patient subgroups, Tango Therapeutics aims to establish a strong competitive position within the rapidly evolving landscape of targeted cancer therapies.